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Abstract: The HIV-1 Gag p6 protein regulates the final abscission step of nascent virions from the cell
membrane by the action of its two late (L-) domains, which recruit Tsg101 and ALIX, components
of the ESCRT system. Even though p6 consists of only 52 amino acids, it is encoded by one of
the most polymorphic regions of the HIV-1 gag gene and undergoes various posttranslational
modifications including sumoylation, ubiquitination, and phosphorylation. In addition, it mediates
the incorporation of the HIV-1 accessory protein Vpr into budding virions. Despite its small
size, p6 exhibits an unusually high charge density. In this study, we show that mutation of the
conserved glutamic acids within p6 increases the membrane association of Pr55 Gag followed by
enhanced polyubiquitination and MHC-I antigen presentation of Gag-derived epitopes, possibly due
to prolonged exposure to membrane bound E3 ligases. The replication capacity of the total glutamic
acid mutant E0A was almost completely impaired, which was accompanied by defective virus release
that could not be rescued by ALIX overexpression. Altogether, our data indicate that the glutamic
acids within p6 contribute to the late steps of viral replication and may contribute to the interaction
of Gag with the plasma membrane.
Keywords: HIV-1; Gag p6; L-domains; virus budding; membrane association; ESCRT; Tsg101;
ALIX; ubiquitination
1. Introduction
The HIV-1 Gag polyprotein Pr55 is necessary and sufficient for the generation of virus like particles
(VLPs) [1,2]. Starting with, or shortly after virus release, Gag is processed by the viral protease (PR)
into its structural components matrix (MA), capsid (CA), nucleocapsid (NC), and its C-terminal p6
protein, as well as the two spacer peptides SP1 and SP2. Upon activation of PR, the Gag components
undergo structural rearrangements within the virion, leading to the formation of a cone shaped core
structure, which is typical for an infectious virus particle [3]. MA directs the Gag polyprotein to the
plasma membrane and lines the inner shell of the mature virion [4,5]. CA constitutes the conical core
enclosing the NC, which mediates uptake and condensation of the viral genome into newly formed
virions [6,7]. The C-terminal p6 region of Gag regulates the membrane fission of nascent virions from
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the cell surface by the action of its two late assembly (L-) domains. The primary L-domain, the PTAP
tetrapeptide motif, mediates the recruitment of Tsg101 (tumor susceptibility gene 101) to the site of
virus assembly [8–11]. The secondary L-domain constituted by the YPX3L motif regulates the binding
of Gag to ALIX (ALG-2 interacting protein X) [12–15]. Although the exact contribution of ALIX to
virus release has not been completely resolved yet, it can restore budding defects under conditions
where binding of Tsg101 to Gag is impaired [13]. Tsg101 and ALIX are both associated to the ESCRT
(endosomal sorting complex required for transport) machinery, which plays pivotal roles in membrane
fission events during membrane protein trafficking and cytokinesis; processes that are topologically
equivalent to virus budding [16–20].
The multifunctional p6 protein undergoes various post-translational modifications, including
sumoylation at Lys-27 and mono-ubiquitination at Lys-27 and -33 [21–23]. Furthermore, it is the
predominant phosphoprotein of HIV-1 particles [24]. However, the biological relevance of its multiple
modifications still remains to be elucidated [22,25,26]. It has already been shown that mutation of
the highly conserved PTAP motif in p6 causes a severe budding defect [27,28]. Additionally, the
mutation of Ser-40 in p6 to Phe, which frequently emerges upon antiviral treatment, delays CA-SP1
processing and enhances membrane association of Gag, but causes no defect in virus release [25,29–32].
The increase in membrane association of p6 mutants correlates with an augmented entry of Gag
into the UPS (ubiquitin proteasome system) and results in enhanced MHC-I antigen presentation of
Gag-derived epitopes [32,33].
Even though the coding region of p6 is highly polymorphic within the HIV-1 viral genome, it
contains motifs, some of which are highly conserved and enable interaction with several cellular
(ERK-2, aPKC, ALIX, Tsg101, SUMO-1, ubiquitin) and viral (Vpr) proteins [8–10,12,21,22,26,34–37].
Alignment of group M consensus sequences revealed that p6 contains seven conserved Glu
residues, which contribute to a calculated isoelectric point of 4.48, not counting the potential
phosphorylation sites. In this study, we demonstrate that mutation of these Glu residues within
p6 to Ala impairs Gag processing and virus release and enhances membrane association of Gag
which is accompanied by increased polyubiquitination and entry of Gag into the MHC-I antigen
presentation pathway.
The cumulative data indicate that these negatively charged Glu residues within p6 contribute to
Gag-membrane-interaction and thus to the late functions of p6 in virus budding.
2. Materials and Methods
2.1. Cell Culture and Transfection
HeLa cells were maintained in DMEM containing 10% (v/v) inactivated fetal calf serum (FCS),
2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. HeLa-Kb cells were cultivated
in DMEM with additional 1 mg/mL geneticin. All cell culture media and reagents were purchased
from Gibco (Life Technologies, Carlsbad, CA, USA).
HeLa cells were transfected with Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol. 24 h post transfection cells were lysed in RIPA buffer (150 mM NaCl,
50 mM Tris-HCl pH 8.0, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 10 mM EDTA) containing
protease inhibitor cocktail cOmplete (Roche, Mannheim, Germany), 5 mM N-ethylmaleimide (NEM),
and 1 mM phenylmethylsulfonylfluoride (PMSF).
2.2. Cultivation and Preparation of Primary Cells
Human tonsils were received a few hours after excision, during routine tonsillectomy, from
the Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsklinikum Erlangen,
Germany. The cells were prepared and infected as described earlier [37,38]. Human lymphocyte
aggregate cultures (HLAC) were prepared by cutting the tonsils into small blocks of 2–3 mm and
grinding the tissue through the sieve of a cell strainer (70 µm, BD Falcon, Bedford, MA, USA) with
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a syringe plunger. Cells were seeded in a 96 well plate at a concentration of 2 ˆ 106 cells per well.
HLACs were cultured in RPMI 1640 supplemented with 15% (v/v) inactivated FCS, 2 mM L-glutamine,
100 U/mL penicillin and 100 µg/mL streptomycin, 2.5 µg/mL Fungizone, 1 mM sodium pyruvate, 1%
(v/v) MEM non-essential amino acid solution and 50 µg/mL gentamicin.
2.3. Investigation of Gag Processing by Steady State Analyses
HeLa cells were transiently transfected with pNLenv1 wt, or the Glu mutants thereof, carrying
Glu to Ala mutations, either from the N- or from the C-terminus of p6. After over-night cultivation
at 37 ˝C the cell culture supernatant was harvested and VLPs released into the supernatant were
pelleted through 20% (w/v) sucrose by centrifugation (20,000ˆ g, 4 ˝C, 90 min), washed with ice
cold PBS, centrifuged (20,000ˆ g, 4 ˝C, 90 min), and lysed in SDS-PAGE sample buffer containing
2% SDS. The cells were detached and washed twice in ice-cold PBS and lysed in RIPA buffer (see
Section 2.1) supplemented with 1 mM PMSF, 5 mM NEM, and protease inhibitor cocktail cOmplete
(Roche). The samples were analyzed by western blotting (see Section 2.6).
2.4. Time Course Analyses of VLP Release
HeLa cells were transiently transfected with pNLenv1 wt, or the Glu mutants E6-29A or E0A. 24 h
post transfection, cells were detached and washed twice in ice-cold PBS. After resuspension in RPMI
1640 medium, cells were aliquoted into 1.5 mL reaction tubes and incubated while gentle shaking at
37 ˝C for the indicated time periods. Cells were collected by centrifugation (3000ˆ g, 4 ˝C) and lysed
in RIPA buffer (see Section 2.1) supplemented with 1 mM PMSF, 5 mM NEM, and protease inhibitor
cocktail cOmplete (Roche). VLPs released into the cell culture supernatant were pelleted through
20% (w/v) sucrose by centrifugation (20,000ˆ g, 4 ˝C, 90 min), washed with 1 mL PBS, centrifuged
(20,000ˆ g, 4 ˝C, 90 min) and directly lysed in 2% SDS sample buffer. All samples were standardized
for protein levels, analyzed by western blotting, stained with antibodies and processed in parallel
as described below (see Section 2.6). To determine the quantity of VLPs released from the cells, the
amount of CA in the VLP fraction was calculated relative to the total amount of Gag present intra-
and extracellularly.
2.5. Detection of Ubiquitinated Gag
Detection of ubiquitinated Gag was carried out as described earlier [32,39]. Inactivation of the viral
protease (PR´) was carried out by adding Nelfinavir to a final concentration of 10 µM upon transfection.
HeLa cells were lysed with RIPA buffer containing protease inhibitors. Lysates were adjusted to 1%
SDS (w/v) and denatured at 95 ˝C for 10 min, subsequently diluted 10 fold, and were then cleared
by centrifugation at 20,000ˆ g for 10 min. Gag content was recovered by immunoprecipitation with
antibodies from HIV-1 patient sera pre-bound to GammaBind Plus Sepharose (GE Healthcare, Little
Chalfont, UK).
2.6. SDS-PAGE and Western Blotting
Protein samples were separated by SDS-PAGE [40] and subsequently transferred onto PVDF
membranes (GE Healthcare). Membranes were blocked with 3% bovine serum albumin and incubated
with the appropriate primary antibody (Ab). Gag was detected by a rabbit Ab recognizing CA
(Seramun, Heidesee, Germany). The mouse anti-transferrin receptor antibody was purchased from
Life Technologies and the anti-β-actin antibody from Sigma-Aldrich (St. Louis, MO, USA). The
anti-mouse and anti-rabbit secondary antibodies coupled to HRP were obtained from Dianova
(Hamburg, Germany). Tagged proteins were detected by monoclonal antibodies (mAb) directly
conjugated to horse radish peroxidase (HRP) specific for HA (Roche, Basel, Switzerland) or FLAG
(Sigma-Aldrich, St. Louis, MO, USA). Protein bands were quantified using AIDA [41].
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2.7. Expression Plasmids
The plasmid for expression of hemagglutinin (HA)-tagged ubiquitin (HA-Ub) was kindly
provided by Hans-Georg Kräusslich [23]. The FLAG-ALIX expression construct is described
elsewhere [42]. The pNL4-3 [43] derived expression constructs pNLenv1 wt [44], the ∆PTAP mutant [29],
or the G2A mutant [32] have been described previously. The codon optimized Gag expression plasmids,
containing the SL sequence and harboring wt p6 or the exchange of the two PTAP motifs, have
been described elsewhere [33,45]. All mutations concerning the Glu residues were introduced by
site-directed mutagenesis (QuikChange® Lightning; Agilent Technologies, Santa Clara, CA, USA)
using complementary primers.
2.8. Flow Cytometry
For detection of H2-Kb-bound SL-epitope, cells were stained with the allophycocyanin
(APC)-conjugated 25D1.16 mAb (eBioscience, San Diego, CA, USA) diluted 1:100 in FACS buffer
(5% (v/v) FCS, 0.02% (v/v) NaN3 in PBS). For intracellular Gag staining, cells were permeabilized
using Cytofix/Cytoperm (BD Bioscience, San Jose, CA, USA). Gag was detected by staining with
a FITC-labeled anti-CA mAb (KC57; Beckman Coulter, Brea, CA, USA) diluted 1:100 in Perm/Wash
buffer (BD Bioscience). Flow cytometry was performed on a BD™ LSR II flow cytometer using
BD FACSDiva™ software (BD Bioscience). Data were analyzed by using the FACS Express V3
software [46].
2.9. Single Round Infection Assay
HeLa TZM-bl indicator cells were seeded in 96-well plates in duplicates (4000 cells/well) and
infected the next day with 1 ng VSV-G-pseudotyped virions standardized for p24 content by ELISA
(Aalto Bio Reagents, Dublin, Ireland). After overnight incubation, fresh medium was added. 48 h
later, cells were washed with PBS and infection was detected using the Gal-Screen chemiluminescent
reporter gene assay system (Applied Biosystems, Waltham, MA, USA). β-Galactosidase activity was
quantified as relative light units per second using a Synergy HT microplate reader and Gen5 Data
Analysis Software (BioTek, Winooski, VT, USA).
2.10. Infection of HLA Cultures
For infection of HLA cultures (see Section 2.2), 2 ˆ 106 cells were infected overnight with virus
preparations equivalent to 1 ng of p24, and cell culture supernatant was collected every second or
third day post infection.
2.11. Determination of the Replication Capacity
Virus replication was assessed by quantification of the virus-associated reverse transcriptase
activity by [32P]-TTP incorporation, using an oligo(dT)-poly(A) template as described elsewhere [47].
To determine the replication capacity of HIV-1 following infection with the indicated HIV-1NL4-3
variants, the respective replication profiles were depicted as diagram (y-axis: RT activity; x-axis: dpi).
2.12. Membrane Flotation
The protocol for membrane flotation was adapted from [39]. Briefly, HeLa cells were extensively
washed and scraped in homogenization buffer (0.25 M sucrose, 1 mM EDTA, 20 mM Tris HCl pH 8.0)
and lysed by sonication. The post-nuclear supernatant was adjusted to 40% iodixanol (OptiPrep;
Axis Shield, Dundee, UK) and underlayed to 28% and 2.5% iodixanol. Samples were centrifuged
at 109,000ˆ g for 3 h. Seven fractions were collected from the top of the gradient and analyzed by
western blot.
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2.13. Peptide Synthesis
The stepwise solid-phase synthesis of the peptide amide was performed on an automated
Odysse microwave peptide synthesizer from CEM on a 0.1 mM scale, using conventional Fmoc/tBu
strategy (HBTU, DIEA, NMP). As solid support H-Gln(Trt)-HMPB-ChemMatrix resin (130 mg, loading
0.47 mmol/g) from pcas Biomatrix was used. The first 10 amino acids were coupled according to
standard methodologies in an automated single coupling mode (50 ˝C, 300 s) all other 600 s. Fmoc
deprotection was carried out with 0.1 M HOBt, 5% Piperazine in DMF (50 ˝C, 300 s). Cleavage of crude
peptides from the resin was accomplished through treatment with 95% TFA, 2.5% water, 2.5% TIPS for
3.5 h. Preparative purification by high-pressure liquid chromatography (HPLC) was carried out on
a Shimadzu LC-8A system with a VariTide RPC column (21.2 mm ˆ 250 mm) and a water/acetonitrile
system (Buffer A: 0.2% TFA in water, Buffer B: 0.2% TFA in water:acetonitrile, 1:4).
The purified peptides were dried by lyophilization and characterized by analytical HPLC and
mass spec analysis.
2.14. NMR Spectroscopy
Prior to NMR analysis of p6E0A, the protein was dissolved in 600 µL 50% aqueous TFE-D2
and transferred to a Wilmad 528-PP-7 NMR tube. TFE-D2O was delivered by Cambridge Isotope
Laboratories, Inc. (Tewksbury, MA, USA). The sample concentration was 2 mM. The 1D and
2D 1H NMR experiments (Total Correlation Spectroscopy (TOCSY), Nuclear Overhauser Effect
Spectroscopy (NOESY) and Correlation Spectroscopy (COSY)) were performed at 600.13 MHz on
a Bruker Avance 600 MHz instrument equipped with an UltraShield Plus magnet and a triple resonance
cryoprobe with gradient unit [48]. The 2D NMR experiments were performed at 300 K without
spinning with mixing times of 110 ms for the TOCSY experiments and 250 ms for the NOESY
experiments, respectively.
3. Results
3.1. Mutation of the Glutamic Acids in p6 Impairs Virus Budding and Gag Processing
Figure 1 shows the primary and secondary structure of p6 derived from the isolate HIV-1NL4-3 [43]
as well as consensus sequences of p6 proteins derived from the M-group viruses. Despite its
polymorphic character, p6 contains some highly conserved amino acid positions as depicted below.
Intriguingly, all known functional sites within p6, such as the two previously described late assembly
(L-) domains PTAP [27,28] and YP(X)nL [12,15] as well as the LXXLF motif, mediating Vpr incorporation
into budding virions [49], overlap with these highly conserved regions. Containing 5 positive and 9
negative charges, p6 displays an unusually high charge density, which might also be controlled by
phosphorylation. It has already been described that phosphorylation of p6 at position 40 by aPKC [36]
and at residue Thr-23 by Erk-2 [35] plays a role in virus release and infectivity, although its biological
function is still under debate [25,31].
Interestingly, most of the Glu residues within p6 are highly conserved among different M-group
strains. However, the function of Glu residues with regard to virus assembly, budding, and Gag
processing has not been investigated yet. For this reason, we conducted Ala scanning mutations
with successive Glu to Ala exchanges in position 6, 12, 13, 19, 20, 29, and 34 of p6. These cumulative
mutations, starting either from the N- or the C-terminus of p6, were introduced in the HIV-1 Gag
expression plasmid pNLenv1 [44]. The p6 mutant, completely devoid of Glu residues, was further on
termed E0A. Serendipitously, the introduced Glu to Ala mutations did neither alter the amino acid
sequence of the overlapping protein p6*, nor of the PR. For functional studies it was important that PR
was not influenced at all, which was not the case as the overlapping protease gene starts at position 40
of the p6 ORF.
Initially, HeLa cells were transiently transfected with mutants carrying successive Glu to Ala
substitutions either from the N- to the C-terminus of p6, or the other way round, respectively. Western
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blot analyses of whole cell lysates and VLP fractions showed a dose-dependent (in terms of the number
of Glu to Ala exchanges) defect in Gag processing with an accumulation of processing intermediates p41
(MA-CA-NC), p39 (MA-CA), and p25 (CA-SP1) (Figure 2A,C). This deficiency in Gag processing was
most pronounced for the E0A mutant, which displayed a Gag processing defect of about 50% compared
to that of the wt (Figure 2B,D). VLP release of the E6-13A mutant was reduced to approximately 95%
that of the E6-20A mutant reaches about 85%, and the E6-29A mutant shows approximately 75% of
the VLP release compared to the wt. A similar picture can be observed for the C- to N-terminal Glu
mutants, where the E34-19A mutant shows about 95%, and the E34-12A mutant about 85% of wt VLP
release (Figure 3A). Even though VLP release does decline in the same extent as the Gag processing
defect upon mutation of the Glu residues, a maximal decrease in VLP release up to 40% of wt level
was solely detected for the total E0A mutant. A stepwise effect of the intermediate mutants was only
detectable for the accumulation of processing intermediates but hardly for the decline in virus release.
(Figure 2B,D). The consecutive exchanges of the glutamic acids from either the N- or the C-terminus of
p6 had similar effects on Gag processing and virus budding, indicating a position independent role of
Glu residues in late functions of p6. Similar to other p6 mutants (∆PTAP, S40F [29,32,33]) the defect in
Gag processing was particularly manifested by accumulation of the processing intermediate CA-SP1
(p25), indicating a delay in the final Gag processing step.
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Figure 1. Amino acid sequence of p6 derived from the isolate HIV-1NL4-3 with previously identified
structural and functional domains [50], charge distribution and sites of posttranslational modifications.
Delineated in red are conserved Glu residues at positions 6, 13, 19, 20, 29, and 34. Positively and
negatively charged residues, previously identified phosphorylation sites for ERK-2 and aPKC [35,36],
attachment sites for ubiquitin [21] and SUMO-1 [22], binding domains for Tsg101 [8–10,34,51], ALIX [12],
and Vpr [49] and structural domains identified by NMR [50] are indicated. Consensus sequences of p6
proteins derived from the M-group viruses [52] were aligned and conserved amino acids are boxed
in grey.
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Figure 2. Successive mutation of glutamic acids in p6 leads to a dose-dependent defect in Gag
processing and impaired VLP release. (A,C) HeLa cells were transiently transfected with the HIV-1
expression plasmid pNLenv1, coding either for the wt or mutants carrying Glu to Ala mutations, either
from the N- (A) or from the C-terminus (C) of p6. Whole cell lysates and VLP fractions were analyzed
by western blotting using anti-CA antibodies (B,D). The VLP release was calculated as the amount of
CA in the VLP fraction relative to the total amount of Gag detected in cell and VLP fractions. Values on
the y-axis were adjusted to 100% for wt. Rate of Gag processing was calculated as the amount of CA
relative to the total amount of Gag in each VLP fraction. Resulting ratios were normalized by mean of
all values of each experiment (adapted from [53]). Values on the y-axis represent arbitrary units. Bars
represent the mean values of 3 independent experiments ˘ SD.
To further investigate the role of the Glu residues in budding and maturation, short term VLP
release kinetics were conducted as described previously [33,54] and analyzed by western blot. The Glu
mutant E6-29A, in which all glutamic acids are substituted, except for Glu-34, displayed a moderate
decline in VLP release, while budding of the E0A mutant was clearly attenuated (Figure 3A). Although
the efficiency of VLP release was only slightly affected as long as one Glu residue was present, Gag
processing of the E6-29A mutant was significantly disturbed with pronounced accumulation of p25
(Figure 3A). Densitometric analyses of the western blot data illustrate that VLP release of the E6-29A
mutant was only slightly reduced, by approximately 20%, whereas that of the E0A mutant was
significantly diminished, by about 70% (Figure 3B). Consistent with data from steady state analyses
(Figure 2), kinetic analyses revealed that both mutants exhibited reduced Gag processing, while only
the E0A mutant showed maximal reduction in VLP release (Figure 3C).
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Figure 3. Mutation of all glutamic acids within p6 inhibits VLP release and Gag maturation. (A) HeLa
cells were transiently transfected with pNLenv1 wt or the Glu mutants E6-29A and E0A. VLP release
was quantified by western blot time course analyses; (B) The percentage of VLPs released over time was
calculated as the amount of CA detected in the VLP fraction versus the total amount of Gag recovered
from cell and VLP fractions; (C) Gag processing was calculated as the amount of CA relative to the
total amount of Gag in the VLP fraction. Values on the y-axis was adjusted to 1 for wt at t = 0.
3.2. Effect of Glu Mutants on Viral Infectivity and Replication Capacity
Having shown that the Glu residues seem to ontribute to the function of p6 in late processes,
we determined the influence of those Glu mutants on viral infectivity in single round infection
assays. HeLa TZM-bl reporter cells were infected with VSV-G pseudotyped virions and infectivity
was measured by β-galactosidase assay (Figure 4A). Consistent with data on Gag processing
(Figures 2 and 3) the E0A mutant exhibits reduced infectivity almost in the range of the ∆PTAP
mutant. Since the infectivity rate was clearly diminished for the total Glu mutant E0A, it was legitimate
to assume that the replication capacity of HIV-1 might also be affected by Glu mutations. Thus,
HLACs (human lymphoid aggregate cultures), prepared from human tonsil tissue, were infected with
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HIV-1NL4-3 virus preparations standardized for p24, either wt or successive Glu to Ala mutants from
the C- to the N-terminus. Measuring the RT activity revealed a stepwise decline of the replication
capacity the more Glu residues were exchanged, resulting in complete loss of replication for the E0A
mutant (Figure 4B), which was again comparable to the replication incompetent ∆PTAP mutant.
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Figure 4. Mutation of glutamic acids reduces the infectivity and replication capacity of HIV-1.
(A) TZM-bl cells were infected with SV-G pseudotyped pNLenv1 VLP stocks, standardized for p24.
I fectio s titers ere eter i e by eas ri g t e -galactosidase activity. ars re rese t t e ea
al es f 3 independent experiments˘ SD; (B) Infection of human lymphoid aggregate cultures (HLAC)
with 1 ng virus standardized for p24 of HIV-1NL4-3 wt or the respective Glu mutants. Replication was
assessed by quantification of the reverse transcriptase activity in cell culture supernatant collected
every second or thir day post i fection (dpi) during 15 days of cultivation.
3.3. Budding Defect of the E0A utant Cannot Be Rescued by Overexpression of ALIX
The budding defect of ∆PTAP utants can be reversed by overexpression of the cellular protein
ALIX, which binds to the secondary YP(X)nL L-domain and interacts with the ESCRT complex [12–14].
Next, we investigated whether ALIX overexpression can also restore the defect in virus release
observed for the E0A utant. After coexpression of pNLenv1 wt, the ∆PTAP or the E0A utant with
FLAG-tagged ALIX in HeLa cells, whole cell lysates and VLP fractions were analyzed by western blot
stained with anti-CA antibodies. Calculation of the amount of CA in the VLP fraction relative to the
total amount of Gag (Figure 5) revealed the typical budding defect of the ∆PTAP mutant that could be
clearly rescued by ALIX overexpression. In contrast, ALIX had virtually no effect on the E0A mutant,
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neither in terms of Gag processing nor in terms of VLP release. To exemplify the delay in p25/24
processing for the E0A mutant, a long time exposure of western blot analysis of virus and cell fractions
derived from wt, ∆PTAP, and E0A expressing HeLa cells is shown in Figure S1.Viruses 2016, 8, x 10 of 22 
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Figure 5. Defect in virus release of the E0A mutant cannot be rescued by ALIX overexpression.
(A) HeLa cells were co-transfected with pNLenv1 expression plasmi s coding for wt, ∆PTAP or E0A
and with FLAG-ALIX or empty c ntrol plasmids, respectively. VLP fractions and whole c ll lysates
were analyzed by w stern blot using an anti-CA. ALIX expression was d tected using anti-FLAG
antibodies; (B) VLP rel ase was calculat t of CA in the VLP fraction relative to the
total mount of Gag det cted in cells and VLPs. resent the mean values of 3 independent
experiments ˘ SD. Values on the y-axis t 100 for wt.
3.4. The Glu Residues in p6 Contribute to the Entry of Gag into the UPS
According to previous studies, mutation of either PTAP or Ser-40 leads to increased
polyubiquitination and enhanced MHC-I antigen presentation of Gag-derived epitopes [23,29,32,33,39,55].
For that reason, we wanted to know whether the Glu residues also affect the ubiquitination and
thus the entry of Gag into the UPS. To address this question, HeLa cells were co-transfected with
HA-tagged ubiquitin (HA-Ub) and pNLenv1 wt, or the respective Glu mutants as indicated. After
immunoprecipitation with Gag-specific antibodies, western blot analyses of precipitated Gag species
were stained for HA (Figure 6A). Following co-expression of pNLenv1 wt and HA-Ub, a specific pattern
of high molecular weight species was observed, which most likely represents polyubiquitinated Gag.
Upon gradual mutation of the Glu residues from the N- or from the C-terminus of p6, the intensity of
the HA-Ub-signal was i creased and reac e its maximum level for the E0A muta t, irrespective of
the direction of the consecutive Glu mutations (Figure 6A,B; lane 4–8).
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Figure 6. Successive mutation of the glutamic acids in p6 gradually increases HIV-1 Gag ubiquitination.
(A,B) HeLa cells were co-transfected with HA-tagged ubiquitin and pNLenv1 expression plasmids as
indicated. Gag was immunoprecipitated from whole cell lysates using anti-HIV antibodies and Gag
ubiquitination was detected by western blot stained for HA. The amount of precipitated Gag was
detected by anti-CA staining.
It has already been well established that K48-linked polyubiquitination functions as a signal to
direct proteins, and also HIV-1 Gag, into the proteasomal degradation pathway [56,57]. In the context
of the HIV-1 p6 protein, mutations of the PTAP L-domain and Ser-40 have been demonstrat d to
cause elevated MHC-I pr sentation of Gag-derived epitopes as a result of an enhanced K48-linked
polyubiquitinatio of Gag [32,33]. Since mutation of Glu residues increased th polyubiquitination of
Gag (Figure 6), i was legitimate to investigate the MHC-I antigen presentation of Gag in this context.
In our previous studies, we thoroughly demonstrated that the measurement of the presentation of
Gag-derived epitopes on MHC-I molecules at the cell surface represents a highly sensitive and reliable
approach to follow up the entry of Gag into the UPS [32,33,45,58].
As there are no antibodies available that efficiently recognize Gag-derived epitopes in the context
of MHC-I, the ovalbumin-derived model epitope SIINFEKL (SL) was introduced into the p2 spacer
region of Gag [45,59]. The pNLenv1-SL expression plasmids, coding either for wt Gag or the respective
Glu mutants, were then transfected into HeLa cells, which stably express the murine MHC-I allotype
H2-Kb (HeLa-Kb [60]). Subsequently, antigen presentation was measured using the mAb 25D1.16,
which specifically recognizes SL in complex with H2-Kb molecules [58].
Consistent with the data on Gag polyubiquitination (Figure 6), flow cytometry analyses revealed
that progressive Glu mutation, either from the N- or from the C-terminus of p6, causes the presentation
of increasing amounts of H2-Kb-SL complexes at the cell surface (Figure 7) with the maximum reached
for the total Glu deficient mutant E0A. Cells expressing E0A p6 displayed even an 8 times higher SL
presentation, when compared to wt expressing cells. The MFI of intracellular Gag staining is shown in
Figure S2. Altogether, these results emonstrate that Glu mutations enhanc Gag polyubiquitination
and entry of Gag into the MHC-I antigen presentation pathway.
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Figure 7. Successive mutation of the glutamic acids within p6 progressively increases the MHC-I
antigen presentation of Gag-derived epitopes. HeLa-Kb cells were transiently transfected with
pNLenv1-SL expression plasmids coding for wt or the sequential Glu mutants of p6 from (A) the
N- to the C-terminus or (B) the C- to the N-terminus, respectively. H2-Kb-SL complexes presented on
the surface of Gag-positive cells were quantified by flow cytometry using the mAb 25D1.16-APC [58].
After fixation and er ea ilization, intracellular Gag was stained with anti-Gag Ab KC57-FITC.
The mean fluoresce c intensity (MFI) of the 25D1.16 staining, n rmalized to the MFI of the
intracellular a ti-Gag staining (see Figure S2) is shown. Bars represent mean values ˘ SD from
three independent experiments.
3.5. Effect of Glu Mutations on the Structure of p6
Recently, we reported that the secondary structure of the p6 mutant S40F, which resembles that
of the wt protein, seems to be present and functionally important as a determinant for membrane
interaction of HIV-1 Gag [32]. The augmentation of membrane interaction of Pr55 Gag in case of the
S40F mutant was caused by formation of a helix-dependent hydrophobic patch, consisting of Tyr-36
and Phe-40, which are close in space at the same surface of the C-terminal helix of p6 [32].
The E0A mutant, where all negatively charged Glu residues have been replaced with more
hydrophobic Ala residues, is characterized by a reduced charge density compared with the wt protein.
First, we wanted to investigate any potential effect of Glu residues on the secondary structure of
p6. With exception of Glu-34, most Glu residues of wt p6 are not incorporated into regions with
well-defined secondary structure. However, Glu-12, -13, -19, and -20 are located adjacent to the short
N-terminal α-helix which is comprised by residues 14–18 [48,50]. Thus, it was essential to reveal if
insertion f multiple Ala residues in the regions adjacent to the N-t rminal α-helix of p6, the single
mutation at position 29 in the flexible inter-helical region of the prot in, and th Ala exchange at
position 34 within he C-t rminal α-helix could influence the extent and position of the secondary
structure of p6.
To i vestigate wheth r the multiple mutations of Glu residues of p6 had a y effects on the position
and extent of secondary structure of the protein at atomic resolution, NMR spectra of the E0A mutant
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dissolved in H2O-TFE-D2 (1:1) were obtained. It has been well established that α-proton chemical
shifts greater than 0.1 ppm relative to the random coil values are qualitative indicators of protein
secondary structure. A minimum of four adjacent residues with an upfield shift are indicative of
an α-helix, whereas β-sheets require a minimum of three residues with downfield shifts [61]. After
spectral assignment (Table S1), chemical shift index (CSI) plots were calculated (Figure 8) to indicate
the location of the α-helical structure. In comparison to the wt protein mutation of Glu-12, 13, 19
and 20 to Ala led to an extension of the N-terminal α-helix of the E0A mutant which now includes
residues 12–20 (Figure 8). On the other hand, mutation of Glu-29 and -34 to Ala did not influence the
secondary structure of the protein (Figure 8). In summary, mutations of Glu to Ala, exemplified by
the E0A mutant, cause enforcement of the α-helical structure of p6, particularly with extension of the
N-terminal helix.
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Figure 8. Mutation of Glu residues to Ala exte s t e -ter i al -helix of p6. Chemical shift
differences (ppm) of the α-protons betw en the experimental values and those f r residu in a ra dom
coil for p6 wt [50] compared with the E0A mutant in 50% aqueous TFE-D2 at pH 3 at 300 K. All positive
values f r N-terminal residues adjacent to proline residues arise from an inherent effect of prolin and
not out of a structural perturbation, as desc ibed in ref. [62].
3.6. Mutation of Glu Residues Enhances e brane Association of Gag
It was previously reported that enhanced membrane association of Gag is a prerequisite for
its recognition by the cellular ubiquitination machinery, regardless of the presence of specific
motifs [39]. Particularly, mutation of the PTAP L-domain has been shown to increase ubiquitination
of Gag, dependent on its ability to bind to the plasma membrane [39,63]. Furthermore, it has been
demonstrated that exchange of Ser-40 to Phe in p6 causes the formation of a hydrophobic patch
which increases the membrane association and, as a consequence, enhances the polyubiquitination of
Gag [32].
As we have already demonstrated that removing all Glu residues within p6 resulted in impaired
virus release, Gag processing, infectivity and replication capacity, as well as in elevated Gag
Viruses 2016, 8, 117 14 of 22
ubiquitination, and enhanced MHC-I antigen presentation, we investigated the impact of these
mutations on membrane association of Pr55 by membrane flotation assays. HeLa cells were transiently
transfected with the codon-optimized synthetic gag gene, syngag, which is expressed from a CMV
promotor driven expression plasmid [64,65]. After whole cell lysis and density gradient centrifugation,
7 fractions were collected from the top of the gradient and the amount of Gag was determined by
western blotting. As positive and negative controls, respectively, we used the myristoylation deficient
MA G2A (∆myr) mutant, which displays a severely reduced membrane binding capacity [66,67], and
the ∆PTAP mutant, that exhibits high levels of membrane-bound Gag [39]. To distinguish between
membranous and cytosolic fractions, antibodies against β-actin and the membrane-bound transferrin
receptor (TfR) were employed. Thereby, fractions 1 and 2 could be identified as membrane-containing,
and fractions 5 to 7 as cytosolic layers.
In line with the augmentation of both polyubiquitination and MHC-I antigen presentation, the
E0A mutation increases the membrane association of Gag in comparison to the wt protein (Figure 9A).
Densitometric analyses revealed that mutation of all Glu residues leads to an accumulation of Gag in
the membranous fractions to the same extent as measured for the ∆PTAP mutant (Figure 9B). The p6
constructs with stepwise Glu mutations showed an intermediate phenotype in terms of membrane
association regardless of number and respective positions of mutated Glu residues. This intermediate
effect coincides with the observed effects of these mutants on Gag processing, ubiquitination and
antigen presentation (Figures 2, 6 and 7).
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Figure 9. The muta ions of Glu resid se the membrane assoc ati n of Pr55 Gag. (A) HeLa
cells were transfected with synga ion constructs coding for wt Gag, the p6 mutants ∆PTAP,
E6A, E6-13A, E6-20A, E6-29A, E0A or the MA G2A mutant (∆myr). The cells were lysed by sonication
and membrane flotation was performed. The fractions were collected and analyzed by western blot
stained for CA. The western blots were reprobed with antibodies specific for β-actin and the transferrin
receptor (TfR) to determine the cytosolic or membrane fractions, respectively. One representative
example of the β-actin and TfR staining is shown; (B) The ratio of Pr55 Gag in the membrane fractions
(1 and 2) vs. the cytosolic fractions (5 to 7) was calculated. Values on the y-axis were adjusted to 1 for
wt. Bars represent the mean values of at least 3 independent experiments ˘ SD.
Taken toge er, these results demonstrate tha the augmentation of polyub quitinatio observed
for th E0A mutant is most likely due to its enhanced membrane association, occurring at a level
comparable to that of the ∆PTAP mutant.
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4. Discussion
The HIV-1 protein p6 has been demonstrated to be essential for budding of viral particles from
the plasma membrane, a main function that is mediated by its primary L-domain PTAP. In contrast,
mutation of the conserved Ser-40 residue to Phe was shown to increase the membrane association and
polyubiquitination of Gag, and to cause aberrant HIV-1 core formation, reduced viral infectivity, and
impaired CA-SP1 cleavage, whereas virus release was not affected [29,30,32]. Furthermore, mutation
of residue Thr-23 of p6, which can be phosphorylated by the kinase Erk-2, was reported to result in
an L-domain-like defect in virus release, aberrant core formation, and reduced infectivity [35], although
a functional link to p6 phosphorylation could not be established in a later study [25]. Despite p6 being
highly polymorphic, all of the established functional sites within p6 represent preserved regions of
the protein.
In this study, we identified the conserved Glu residues as regulatory signals of p6 for membrane
interaction of the Pr55 Gag polyprotein. Furthermore, the removal of these acidic residues causes
enhanced polyubiquitination and subsequent MHC-I antigen presentation of Gag-derived epitopes.
Most astonishingly, the phenotype induced by removal of all Glu residues in p6 seems to occur
completely independent of the ESCRT machinery inasmuch as both L-domains remained intact in p6
E0A, and even overexpression of ALIX did not rescue the budding defect observed for the E0A mutant.
It is commonly accepted that ubiquitin plays an essential role in retrovirus release but its mode
of function has been controversially discussed [68–70]. Although some studies suggested that Gag
ubiquitination contributes to efficient virus particle release via the ESCRT-complex [8,71,72], more
recent studies indicate that ubiquitination of Gag can occur independently of the ESCRT complex and
might be dispensable to drive viral particle release [32,33,63,73,74]. Jager et al. demonstrated that a late
budding arrest causes enhanced ubiquitination of Gag by increasing its membrane association [39].
In concert with these results, we now show that the E0A mutant exhibits increased membrane binding
of Gag, supporting the notion that membrane interaction of Gag is not only dependent on L-domain
function (∆PTAP mutant [39]), but can also be affected by charge distribution (E0A mutant), or
the introduction of a hydrophobic patch (S40F mutant [32]). In case of the S40F mutant, which in
membrane flotation assays shows similarly increased proportions of Gag in the membrane fraction
when compared to the ∆PTAP mutant [32], a direct membrane interaction was demonstrated by
surface plasmon resonance (SPR) spectroscopy [48]. These observations led us to assume that in the wt
situation the Glu residues within p6 might prevent prolonged binding of Gag to the cell membrane via
charge repulsion between negatively charged membranous phospholipids and the negative charges of
Glu residues in p6. This repulsion seems to be indispensable in order to ensure accurate progress of
the late steps of virus replication. To illustrate this conception a preliminary, hypothetical model is
depicted in Figure 10.
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One possible explanation for the enhanced membrane association of the E0A mutant might be
structural alterations induced by the non-conservative amino acid exchanges. To address this question,
solution 1H NMR spectroscopy was conducted, and α-proton chemical shift differences revealed
that mutations of the Glu residues leave the principal positions of the N- and C-terminal α-helices
of p6 intact. Nevertheless, in case of the E0A mutant, the N-terminal helix of p6 is extended by
residues 12, 13, 19, and 20, which most probably contributes to increased membrane binding of Gag
via hydrophobic interactions. Although involvement of E34A in the C-terminal α-helix did not change
its secondary structure, introduction of Ala might also increase the hydrophobicity of this helix and
thus, in total, strengthen the membrane interaction, as observed by others for this C-terminal α-helix
of p6, which appears to have an intrinsic propensity to interact with phospholipid bilayers [75].
Furthermore, it has been reported by others that the Pr55 Gag precursor undergoes a major
conformational change during assembly [76–78]. In these studies, it was proposed that Gag was
compact in solution with MA and NC in close proximity. Once MA anchors Gag to the plasma
membrane, NC is also able to associate with the membrane via electrostatic interactions [77]. Upon
binding of the viral RNA to NC and binding of Gag to the plasma membrane via MA, Gag is
extended to its final conformation and this might be further stabilized by interprotein interactions [77].
Nevertheless, in these studies the authors used a Gag protein lacking the C-terminal p6 domain [76–78].
Membrane flotation assays using the complete Pr55 Gag protein now demonstrate enhanced membrane
binding of Gag after mutation of Glu residues in p6. We propose a hypothetical model by which in the
wt situation the Glu residues within p6 contribute to the extended shape of Gag through repulsion from
the plasma membrane via their negative charges (Figure 10A). In consistency with this hypothesis is the
finding that NC alone displays a strong interaction with the plasma membrane [79]. Ala substitution
of all basic residues in NC significantly decreased membrane association of Gag [80]. Furthermore, it
has been demonstrated that the p6 domain in the context of NCp15 folds back to the NC and interacts
with the basic zinc fingers [81,82]. Conceivably, the nine negatively charged amino acids within p6,
seven of which are constituted of Glu residues, are necessary to prevent prolonged binding of NC to
the membrane via its basic residues, by counteracting its positive net charge.
Recently, it has been reported that duplication of the PTAP motif enhances the efficiency of
NC-SP2-p6 processing in the context of PR mutations and under PI (protease inhibitor) treatment [83],
also suggesting a functional interaction of NC and p6 during assembly and maturation. According to
this, our data confirm that certain motifs in p6 contribute to efficient Gag processing, particularly the
final CA-SP1 cleavage step.
Furthermore, the viral RNA could be identified as a negative regulator of Gag membrane
binding [84,85]. The authors and several other studies showed that HIV-1 MA interacts with the
viral RNA via its HBR (highly basic region) [86–88]. According to Chukkapalli et al., this interaction
negatively influences membrane binding of Gag [84]. Thus, one could speculate that the Glu residues
within p6 contribute to the stretching of Gag upon binding of RNA to NC to finally enable efficient
Gag processing.
Very recently, Wei et al. reported the interaction of Gag with a complex consisting of CCDC8,
Obsl1, and the E3 ligase Cul7 at the plasma membrane, causing K48-linked polyubiquitination of
Gag [63]. Accordingly, our results indicate that enhanced Gag membrane interaction of the E0A mutant
contributes to increased polyubiquitination, which might occur via prolonged exposure to membrane
resident E3 ligases like Cul7 during assembly. This finding is also consistent with the results obtained
for the ∆PTAP and S40F mutants, which exhibit increased K48-linked polyubiquitination [23,32,33,55].
It is commonly known that K48-linked polyubiquitination designates proteins for degradation by
the 26S proteasome [56]. Consistently, the E0A mutant preferentially enters the MHC-I pathway, as it
shows a significantly enhanced presentation of Gag-derived epitopes even though the total amount
of Gag seems not to be affected in steady state analyses. This result is in line with earlier studies,
where an increase in MHC-I antigen presentation was not associated with a significant reduction of the
half-life of Gag [33,45]. One possible reason for this phenomenon might be that only a small fraction
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of all newly synthesized Gag proteins becomes ubiquitinated and is subsequently directed into the
UPS [57]. Moreover, reduction of the rate of Gag processing increases the amount of the Gag precursor,
which is counteracted by proteasomal degradation.
Consistent with our previous studies, it has been shown by others that the efficiency of virus
release was not affected by mutation of Ser-40 [29–32]. In contrast, the E0A mutant, which also
increased Gag membrane binding, displayed a severe budding defect. These results indicate that
the enhanced membrane association of Gag is somehow independent of virus budding, which led
us to the hypothetical conclusion that the Glu residues in p6 fulfill two independent functions,
namely the negative regulation of membrane binding of Gag as well as the maintenance of virus
release. Remarkably, the latter process was only strongly diminished when all Glu residues were
mutated, whereas the number of remaining Glu residues in p6 successively influences processes like
ubiquitination, antigen presentation and Gag processing.
It has been shown previously that the budding defect observed after mutation of the PTAP
motif can be rescued by ALIX overexpression [13]. As we observed that only the total Glu mutant
E0A was completely impaired in virus release, it is legitimate to assume that the budding defect
of the E0A mutant is not related to the well-established function of p6 as a docking site for the
ESCRT system mediated by its two L-domains, inasmuch as both interaction sites for Tsg101 and
ALIX remained vital in these experiments. Since both the ∆PTAP and the E0A mutant succumb to
augmented polyubiquitination, but only the ∆PTAP mutant can be rescued by ALIX overexpression,
one might conclude that the observed E0A phenotype occurs independently of L-domain interaction.
In terms of the Glu residues, these results rather point towards a novel motif within p6 that besides
the two L-domains, contributes to virus release. Nevertheless, one must also take into consideration
that the E0A mutant, as it exhibits structural changes of the N-terminal helix, might have lost the
ability to bind to Tsg101 and/or ALIX leading to the observed budding defect. This disability for
the recruitment of critical ESCRT factors could also contribute to downstream events like increase of
membrane association and polyubiquitination of Gag.
Moreover, it is conspicuous that p6 harbors a very high charge density. It creates the impression
that the charges within p6 in general are necessary components of the protein as they are conserved
among all HIV-1 subtypes aside from the amino acid conservation itself. For example in subtype F1 the
Glu residue at position 34 is exchanged for Gly, which is compensated by an additional Glu residue at
position 33 (Figure 1). Furthermore, the positively charged Arg-42 of the clone HIV-1NL4-3 is replaced
by Lys in all other subtypes. In addition, at position 31, all subtypes display a positively charged Lys
residue. Thus, the high charge density of p6 seems to be important for the functionality of the protein,
to which the Glu residues might contribute. Aside from HIV-1, p6 related proteins of other retroviruses
that appear to be involved in virus release also display a very high charge density, like p9 of the equine
infectious anemia virus (EIAV), p6 of SIV and HIV-2, or p12 of murine leukemia virus (MuLV) [89–91].
Altogether, our results indicate that the duration of Gag at the cell membrane in the course of
assembly and budding is regulated to be as short as necessary to allow the concerted action of virus
release. Delay of Gag at the plasma membrane, caused by removal of the negative charges within p6,
increases its access to E3 ligases such as Cul7 which was shown to disturb virus assembly and to direct
Gag into proteasomal degradation [63].
In case of the E0A mutant, two concomitant mechanisms might contribute to the augmented
membrane association. First, the loss of electrostatic repulsion between negatively charged residues in
p6 and the phospholipid head groups of the cell membrane, and second, the extension of the N-terminal
α-helix attended with the intensification of its hydrophobic character, that might interfere with efficient
Gag assembly but might also negatively influence the interaction with the ESCRT components Tsg101
and/or ALIX leading to impaired virus release. However, one must also take into consideration that
the charge density of p6 might not exclusively be influenced by the number of Glu residues, but might
also depend on alterations in the status of p6 phosphorylation due to Glu mutations.
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5. Conclusions
The cumulative data support a model by which p6 acts as negative regulator of Gag membrane
interaction via its Glu residues, which shortens the duration of Gag at the plasma membrane necessary
for efficient assembly and virus release.
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